Progyny, Inc.
NASDAQ:PGNYMedical - Healthcare Information Services
-$0.05 today
- Market cap
- $2.66B
- Beta
- 1.04
- P/E (TTM)
- 31.4
- EPS (TTM)
- $0.84
Volume 0.88M
Average 1.49M
PGNY EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Progyny, Inc.NASDAQ: PGNY
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA growth accelerates
Q2 FY2026 EBITDA of $44.24M rose 56.4% year over year, ahead of the +36.3% change in trailing-twelve-month EBITDA. Sequentially, it rose 15.3% from the prior quarter. Over 3 fiscal years it compounded at +56.8% a year.
Context
- EBITDA amounted to 7.8% of revenue in FY2025, up 0.4 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of $147.48M (+46.9%) for the fiscal year ending Dec 2026, a step up from the +16.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $44.24M+15.3% QoQ
- Last fiscal yearDec 2025
- $100.38M+16.2% YoY
- LTMJun 2026
- $127.06M+36.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +56.4% | +30.0% | -26.4 pp |
| 1 year | +16.2% | +46.9% | +30.7 pp |
| 3-year CAGR | +56.8% | +26.8% | -29.9 pp |
| 5-year CAGR | +16.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 100.38M USD
- Year-over-year change
- +16.2%
- 4-year CAGR
- +31.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 100.38M | +16.2% |
| FY2024 | 2024-12-31 | 86.38M | +18.4% |
| FY2023 | 2023-12-31 | 72.97M | +180.2% |
| FY2022 | 2022-12-31 | 26.04M | -22.8% |
| FY2021 | 2021-12-31 | 33.74M | — |
EBITDA vs competitors
How PGNY compares with its peers on the latest reported figures
- PGNY's LTM Jun 2026 EBITDA of $127.06M is the 2nd highest of the 3 companies compared; the peer median is $247.78M.
- Its year-over-year change of +36.3% is the 2nd highest of 3, against a peer median of +61.9%.
- EBITDA amounts to 9.7% of revenue for PGNY, versus a peer median of 18.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $495.07M | +22.1% | +41.8% | 36.3% | |
| LTM Jun 2026 | $127.06M | +36.3% | +56.8% | 9.7% | |
| LTM Mar 2026 | $491K | +101.7% | — | 0.2% | |
| Peer median (excluding PGNY) | $247.78M | +61.9% | +41.8% | 18.3% | |
Competitors are the stored peer set for PGNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 500.62M | 786.91M | 1.09B | 1.17B | 1.29B |
| Cost of Revenue | 388.49M | 619.59M | 849.8M | 913.86M | 984.18M |
| Gross Profit | 112.14M | 167.33M | 238.8M | 253.36M | 304.48M |
| Gross Margin | 22.4% | 21.3% | 21.9% | 21.7% | 23.6% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 79.8M | 143.98M | 176.62M | 185.91M | 219.21M |
| Operating Expenses | 79.8M | 143.98M | 176.62M | 185.91M | 219.21M |
| Depreciation & Amortization | 1.3M | 1.6M | 2.28M | 3.18M | 4.95M |
| EBITDA | 33.74M | 26.04M | 72.97M | 86.38M | 100.38M |
| EBITDA Margin | 6.7% | 3.3% | 6.7% | 7.4% | 7.8% |
| Operating Income | 32.34M | 23.34M | 62.18M | 67.46M | 85.28M |
| Operating Margin | 6.5% | 3.0% | 5.7% | 5.8% | 6.6% |
| Interest Income | 461K | 814K | 8.51M | 15.75M | 10.16M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 95K | 1.1M | 8.51M | 15.75M | 10.16M |
| Income Before Tax | 32.44M | 24.44M | 70.69M | 83.2M | 95.43M |
| Pre-Tax Margin | 6.5% | 3.1% | 6.5% | 7.1% | 7.4% |
| Income Tax Expense | (33.33M) | (5.92M) | 8.65M | 28.87M | 36.91M |
| Net Income | 65.77M | 30.36M | 62.04M | 54.34M | 58.52M |
| Net Margin | 13.1% | 3.9% | 5.7% | 4.7% | 4.5% |
| EPS (Basic) | 0.74 | 0.33 | 0.65 | 0.59 | 0.68 |
| EPS (Diluted) | 0.66 | 0.30 | 0.62 | 0.57 | 0.65 |
| Weighted Avg Shares | 89.11M | 92.2M | 95.02M | 91.48M | 85.23M |
| Weighted Avg Shares (Diluted) | 100.36M | 99.96M | 100.67M | 95.45M | 89.46M |
Progyny, Inc.
NASDAQ:PGNY
Intrinsic Alpha fair value
Locked
Current Price
$36.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.